Professor Charlie Craddock on drug therapies for blood cancers

Professor Charlie Craddock on drug therapies for blood cancers


Recent advances in our understanding of the biology of leukemia and other blood cancers
has led to the development a whole range of new and potentially very effective drug therapies so we’re now in a
position with a range of new therapies where there is an onus to test these new drugs as safely and as quickly
as possible What we’ve done in Birmingham since 2006 through the development of the Centre for Clinical Haematology Is identify a early phase trial centre that co-locates patients from one of the largest catchment areas in Europe clinicians and scientists so that we’ve been able over this period to trial up to 25 new drug therapies at the same time we demonstrated that this is a very effective way of job creation and have identified that more than 130 new jobs in the health and biopharmaceutical centre have been generated by this initiative
so this demonstrates real strategic strength that Birmingham has in clinical trialling and a great opportunity scaling these up
with even greater economic benefits so although the development of new
drugs was initially particularly well
demonstrated in leukemia and other cancers it’s also clear that our advances and understanding of the biology of other diseases such as
parkinson’s disease or hypertension is also going to lead to very important
new biologically based therapies and we believe there is going to be a
similar importance and imperative in providing an appropriate clinical trials
infrastructure and network to assess therapies in non-malignant disease as well so our aim as we go forward is to
create an institute of translational medicine that’s gonna cover the whole range of
human disease prioritizing the safe and rapid assessment of new therapies in both cancers and other diseases